Clinical Trial Update: Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sequential all-trans retinoic acid (ATRA) followed by interleukin-2 (IL-2) to modulate dendritic cells for treating metastatic renal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ATRA (all-trans retinoic acid) (all-trans retinoic acid)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED